Page 3 of 4: studies 41 to 60 of 75, newest first. Back to the MDMA overview
Psychopharmacology May 7, 2009
Role of dopamine transporters in the behavioral effects of 3,4-methylenedioxymethamphetamine (MDMA) in nonhuman primates.
Neuroscience May 5, 2009 Kevin T. Ball, C L Wellman, E Fortenberry et al.
Repeated, intermittent exposure to the psychomotor stimulants amphetamine and cocaine induces a progressive and enduring augmentation of their locomotor-activating effects, known as behavioral sensitization, which is accompanied by similarly stable adaptations in the dendritic structure of cortico-striatal neurons. We examined whether repeated exposure to the increasingly abused amphetamine...
British Journal of Pharmacology April 30, 2009 Sotiria Bexis, James R. Docherty 36 citations
Background and purpose: We have investigated the ability of the β 3 ‐adrenoceptor antagonist 1‐(2‐ethylphenoxy)‐3‐[[(1S)‐1,2,3,4,‐tetrahydro‐1‐naphthalenyl]amino]‐(2S)‐2‐propanol hydrochloride (SR59230A) to affect the hyperthermia produced by methylenedioxymethamphetamine (MDMA) in conscious mice and whether α 1 ‐adrenoceptor antagonist actions are involved. Experimental approach: Mice were...
Drugs and Alcohol Today April 13, 2009 Zoe R. Smith, Karenza Moore, Fiona Measham 34 citations
Commonly known as ecstasy, MDMA has been central to the British acid house, rave and dance club scene over the last 20 years. Figures from the annual national British Crime Survey suggest that ecstasy use has declined since 2001. This apparent decline is considered here alongside the concurrent emergence of a ‘new’ form of ecstasy ‐ MDMA powder or crystal ‐ and the extent to which this can be...
Neuroscience April 10, 2009 B N Johnson, Bryan K. Yamamoto
Exposure to stress alters the behavioral and neurochemical effects of drugs of abuse. However, it is unknown if chronic stress can affect the serotonergic depletions induced by the psychostimulant drug 3,4-methylenedioxymethamphetamine (MDMA). Rats were exposed to 10 days of chronic unpredictable stress (CUS) which resulted in the predicted elevation of basal plasma corticosterone...
Psychopharmacology April 2009 Thelma Schilt, Anneke E. Goudriaan, Maarten W Koeter et al.
Ecstasy (+/-3,4-methylenedioxymethamphetamine) is a widely used recreational drug that may damage the serotonin system and may entail neuropsychological dysfunctions. Few studies investigated predictors for ecstasy use. Self-reported impulsivity does not predict the initiation of ecstasy use; the question is if neuropsychological indicators of impulsivity can predict first ecstasy use. This...
Addiction Biology April 2009 Ema Alves, Teresa Summavielle, Cecília Juliana Alves et al.
The administration of a neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy') to the rat results in mitochondrial oxidative damage in the central nervous system, namely lipid and protein oxidation and mitochondrial DNA deletions with subsequent impairment of the correspondent protein expression. Although these toxic effects were shown to be prevented by monoamine oxidase B...
The British Journal of Psychiatry March 31, 2009 Sudhakar Selvaraj, Rosa Hoshi, Zubin Bhagwagar et al. 59 citations
Background Animal experimental studies have prompted concerns that widespread use of 3,4-methylenedioxymethamphetamine (MDMA; ‘ecstasy’) by young people may pose a major public health problem in terms of persistent serotonin neurotoxicity. Aims To determine the status of brain serotonin neurons in a group of abstinent MDMA users. Method We assessed the integrity of brain serotonin neurons by...
Physiology & Behavior March 23, 2009 Valerie B Thompson, Justin Heiman, James B Chambers et al.
The current study sought to determine whether prenatal 3,4-methylenedioxy-N-methamphetamine (MDMA) exposure from E14-20 in the rat resulted in behavioral sequelae in adult offspring. Prenatal MDMA exposure results in increased dopaminergic fiber density in the prefrontal cortex, striatum and nucleus accumbens of young rats. Since these areas are critical in response to novelty, reward,...
Journal of Psychopharmacology March 20, 2009
MDMA (ecstasy) use is associated with reduced BOLD signal change during semantic recognition in abstinent human polydrug users: a preliminary fMRI study.
Journal of Psychopharmacology March 9, 2009 P.-ø. Johansen, Ts Krebs 98 citations
Abstract Exposure therapy is known to be an effective treatment for anxiety disorders. Nevertheless, exposure is not used as much as it should be, and instead patients are often given supportive medications such as serotonin reuptake inhibitors (SSRIs) and benzodiazepines, which may even interfere with the extinction learning that is the aim of treatment. Given that randomized controlled trials...
Pharmacology, Biochemistry, and Behavior March 2009 Ronald L Cowan, James M. Joers, Mary S Dietrich
Impaired verbal memory is common in MDMA (Ecstasy) polydrug users. The contributions of Ecstasy or polydrug exposure to reduced verbal memory are unclear, as is the neural basis for this cognitive deficit. Ecstasy users have reduced gray matter in brain regions mediating verbal memory (BA 18, 21 and 45). N-acetylaspartate (NAA) as a neuronal marker and myoinositol (mI) as a glial marker are...
The International Journal of Neuropsychopharmacology March 2009 Anna M S Kindlundh-Högberg, Xiaoqun Zhang, Per Svenningsson
The recreational drug 3,4-methylenedioxy-metamphetamine (MDMA; 'ecstasy') enhances serotonin and dopamine transmission. Repeated binge treatment with MDMA (5 mg/kg, 3 times daily, 3 h apart, once per week for 4 wk) was found to increase gene expression of S100B, a neurotrophic factor that modulates neuronal plasticity. Mutant mice overexpressing S100B were investigated to better understand how...
Annales pharmaceutiques francaises March 2009 M-B Fleury, Anne Neudörffer, Anne Felim et al.
Intracerebroventricular injection of methylenedioxymethamphetamine (MDMA, ecstasy) in rats fails to reproduce long-term toxic effects observed after peripheral administration. Therefore, systemic metabolites would play an essential role in the development of cytotoxicity. In humans, the major metabolite is the 3,4-dihydroxymethamphetamine derivative (HHMA), which is easily oxidizable to the...
Cardiovascular toxicology March 2009 Sylvia K Shenouda, Kurt J Varner, Félix Carvalho et al.
Repeated administration of 3,4-methylenedioxymethamphetamine (MDMA) (ecstasy) produces eccentric left ventricular (LV) dilation and diastolic dysfunction. While the mechanism(s) underlying this toxicity are unknown, oxidative stress plays an important role. MDMA is metabolized into redox cycling metabolites that produce superoxide. In this study, we demonstrated that metabolites of MDMA induce...
Journal of Psychoactive Drugs March 2009 Brian C Kelly
Ecstasy use remains a key concern for professionals working in fields related to youth and drug use. At the forefront of these concerns are issues related to neurological dysfunction and depression--both acute and long-term--associated with MDMA use. Ecstasy users have been shown to assess Ecstasy related harms and to engage in a variety of practices to manage these risks. To contend with risk...
Journal of Neurochemistry February 2009 Elena Puerta, Isabel Hervias, Beatriz Goñi-allo et al.
Phosphodiesterase 5 (PDE5) inhibitors are often used in combination with club drugs such as 3,4-methylenedioxymethamphetamine (MDMA or ecstasy). We investigated the consequences of such combination in the serotonergic system of the rat. Oral administration of sildenafil citrate (1.5 or 8 mg/kg) increased brain cGMP levels and protected in a dose-dependent manner against 5-hydroxytryptamine...
Journal of Psychopharmacology January 22, 2009 Gjh Dumont, Rik C. Schoemaker, Daan J Touw et al. 37 citations
In Western societies, a considerable percentage of young people use 3,4-methylenedioxymethamphetamine (MDMA or ‘ecstasy’). The use of alcohol (ethanol) in combination with ecstasy is common. The aim of the present study was to assess the acute psychomotor and subjective effects of (co-) administration of MDMA and ethanol over time and in relation to the pharmacokinetics. We performed a...
Neurotoxicology and Teratology 2009 Manuel Daza‐losada, Marta Rodríguez‐arias, Concepción Maldonado et al.
The poly-drug pattern is the most common among those observed in MDMA users, with cocaine being a frequently associated drug. This study evaluates the acute effects of MDMA (5, 10 and 20 mg/kg), alone or in combination with cocaine (25 mg/kg), on motor activity, anxiety (elevated plus maze and social interaction test), memory and brain monoamines in adolescent mice. Both drugs, administered...
Archives of Toxicology January 2009 Yoshio Nakagawa, Toshinari Suzuki, Sumiko Tayama et al.
The amphetamine-derived designer drugs have been illegally used worldwide as recreational drugs, some of which are known to be hepatotoxic in humans. To compare their cytotoxic effects, 3,4-methylenedioxy-N-methamphetamine (MDMA) and its related analogues, N-methyl-1-(3,4-methylenedioxyphenyl)-2-butanamine (MBDB), 3,4-(methylenedioxyphenyl)-2-butanamine (BDB) and...